Diamyd Medical Future Growth
Future criteria checks 2/6
Diamyd Medical's earnings are forecast to decline at 21% per annum while its annual revenue is expected to grow at 35.8% per year. EPS is expected to decline by 16.6% per annum.
Key information
-21.0%
Earnings growth rate
-16.6%
EPS growth rate
| Biotechs earnings growth | 39.3% |
| Revenue growth rate | 35.8% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 24 Apr 2024 |
Recent future growth updates
Recent updates
We're Keeping An Eye On Diamyd Medical's (STO:DMYD B) Cash Burn Rate
Feb 02
We Think Diamyd Medical (STO:DMYD B) Needs To Drive Business Growth Carefully
Sep 22What You Need To Know About Diamyd Medical AB (publ)'s (STO:DMYD B) Investor Composition
Jan 22Here's Why Diamyd Medical's (STO:DMYD B) Statutory Earnings Are Arguably Too Conservative
Nov 30Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 8/31/2026 | 3 | -201 | -196 | -196 | 1 |
| 8/31/2025 | 3 | -165 | -160 | -160 | 1 |
| 8/31/2024 | 3 | -133 | -137 | -129 | 1 |
| 2/29/2024 | 0 | -120 | -134 | -122 | N/A |
| 11/30/2023 | 0 | -116 | -124 | -112 | N/A |
| 8/31/2023 | 1 | -116 | -122 | -111 | N/A |
| 5/31/2023 | 1 | -119 | -116 | -119 | N/A |
| 2/28/2023 | 0 | -115 | -122 | -127 | N/A |
| 11/30/2022 | 1 | -99 | -114 | -120 | N/A |
| 8/31/2022 | 0 | -104 | -128 | -93 | N/A |
| 5/31/2022 | 0 | -91 | -153 | -110 | N/A |
| 2/28/2022 | 1 | -106 | -147 | -99 | N/A |
| 11/30/2021 | 0 | -83 | -140 | -95 | N/A |
| 8/31/2021 | 0 | 60 | -114 | -109 | N/A |
| 5/31/2021 | 0 | 74 | -67 | -58 | N/A |
| 2/28/2021 | 0 | 99 | -47 | -43 | N/A |
| 11/30/2020 | 0 | 121 | 5 | 9 | N/A |
| 8/31/2020 | 0 | 10 | 15 | 17 | N/A |
| 5/31/2020 | 1 | 13 | 13 | 13 | N/A |
| 2/29/2020 | 1 | 13 | 11 | 11 | N/A |
| 11/30/2019 | 1 | -35 | -35 | -35 | N/A |
| 8/31/2019 | 2 | -37 | -39 | -39 | N/A |
| 5/31/2019 | 1 | -38 | -38 | -38 | N/A |
| 2/28/2019 | 0 | -43 | -38 | -38 | N/A |
| 11/30/2018 | 0 | -42 | -41 | -40 | N/A |
| 8/31/2018 | 1 | -44 | -42 | -42 | N/A |
| 5/31/2018 | 1 | -39 | -43 | -42 | N/A |
| 2/28/2018 | 1 | -35 | -38 | -38 | N/A |
| 11/30/2017 | 1 | -32 | N/A | -33 | N/A |
| 8/31/2017 | 1 | -26 | N/A | -26 | N/A |
| 5/31/2017 | 1 | -24 | N/A | -20 | N/A |
| 2/28/2017 | 1 | -34 | N/A | -19 | N/A |
| 11/30/2016 | 1 | -32 | N/A | -18 | N/A |
| 8/31/2016 | 1 | -32 | N/A | -18 | N/A |
| 5/31/2016 | 1 | -31 | N/A | -17 | N/A |
| 2/29/2016 | 1 | -20 | N/A | -18 | N/A |
| 11/30/2015 | 1 | -20 | N/A | -17 | N/A |
| 8/31/2015 | 1 | -21 | N/A | -18 | N/A |
| 5/31/2015 | 1 | -20 | N/A | -18 | N/A |
| 2/28/2015 | 0 | -17 | N/A | -17 | N/A |
| 11/30/2014 | 0 | -17 | N/A | -18 | N/A |
| 8/31/2014 | 0 | -16 | N/A | -17 | N/A |
| 5/31/2014 | 0 | -17 | N/A | -17 | N/A |
| 2/28/2014 | 0 | -17 | N/A | -16 | N/A |
| 11/30/2013 | 0 | -18 | N/A | -15 | N/A |
| 8/31/2013 | 0 | -13 | N/A | -14 | N/A |
| 5/31/2013 | 0 | -1 | N/A | -28 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DMYD B is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DMYD B is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DMYD B is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DMYD B's revenue (35.8% per year) is forecast to grow faster than the Swedish market (1.7% per year).
High Growth Revenue: DMYD B's revenue (35.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DMYD B's Return on Equity is forecast to be high in 3 years time